#1 Clinical Trials Search in Europe

Arrhenatherum Elatius

This article discusses clinical trials investigating the use of Arrhenatherum Elatius, a grass pollen extract, as part of a mixture for treating allergic rhinitis and rhinoconjunctivitis caused by house dust mite allergies. The trials aim to assess the effectiveness and safety of subcutaneous immunotherapy using this grass pollen mixture in adults with moderate to severe symptoms.

Table of Contents

What is ARRHENATHERUM ELATIUS?

ARRHENATHERUM ELATIUS is a type of grass pollen that is used in allergy testing and treatment. It is one of several grass pollens included in a mixture used for diagnosing and treating grass pollen allergies[1]. This grass is also known as tall oatgrass or false oat-grass.

Medical Use

ARRHENATHERUM ELATIUS is primarily used in the context of allergy diagnosis and treatment. It is part of a solution used for skin-prick tests, which help doctors identify specific allergens that cause allergic reactions in patients[1]. The product containing this grass pollen is called “HAL Allergy Prick Test Gräserpollen-Mischung,” which is a mixture of various grass pollens used for diagnostic purposes.

Clinical Trial Information

While the provided clinical trial information doesn’t specifically focus on ARRHENATHERUM ELATIUS alone, it does involve a treatment for grass pollen allergies, which likely includes this particular grass species. The trial is studying a treatment called PURETHAL Mites Mixture, which is used for subcutaneous immunotherapy (SCIT) in adults with moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mite allergy[1].

This study aims to assess the effectiveness of the treatment in reducing allergy symptoms and improving quality of life for patients. While it’s not directly about ARRHENATHERUM ELATIUS, the trial provides insight into how similar allergen-based treatments are evaluated.

Administration

In the context of allergy testing, ARRHENATHERUM ELATIUS is administered as part of a skin-prick test. This involves placing a small drop of the allergen solution on the skin, usually on the forearm or back, and then lightly pricking the skin through the drop[1]. The maximum dose for the skin-prick test is typically 1 drop, applied cutaneously (on the skin).

Potential Benefits

The primary benefit of using ARRHENATHERUM ELATIUS in allergy testing is to accurately diagnose grass pollen allergies. By identifying specific allergens, doctors can develop more targeted treatment plans for patients suffering from allergic rhinitis or rhinoconjunctivitis (inflammation of the nose and eyes due to allergies).

Safety and Side Effects

As ARRHENATHERUM ELATIUS is used in a diagnostic capacity, the risks associated with its use in skin-prick tests are generally low. However, as with any allergy test, there is a small risk of an allergic reaction. This is why these tests are always performed under medical supervision.

Who Can Use This Treatment?

The skin-prick test containing ARRHENATHERUM ELATIUS can be used on patients suspected of having grass pollen allergies. However, there are some conditions under which this test should not be performed:

  • Patients with severe immune disorders or diseases requiring immunosuppressive medication
  • Those with active malignancies or any malignant disease in the last 5 years
  • Individuals with severe skin diseases that might affect the test results
  • Pregnant or breastfeeding women (as a precautionary measure)
  • People who have taken antihistamines or other medications that could interfere with the test results (these medications typically need to be stopped for a certain period before the test)

It’s important to note that the decision to perform an allergy test should always be made by a healthcare professional based on the individual patient’s medical history and current health status[1].

Aspect Details
Study Type Randomized, Double-Blind, Placebo-Controlled, Multi-Centre
Condition Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
Treatment PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy
Primary Outcome Average daily Total Combined Rhinitis Score (TCRS) during the last 8 weeks of one-year treatment
Key Inclusion Criteria Adults 18-65 years, HDM allergy history for at least 1 year, positive skin prick test and serum IgE for HDM, FEV1 > 70%
Key Exclusion Criteria Severe immune disorders, active malignancies, uncontrolled asthma, previous HDM immunotherapy
Safety Assessments Adverse events, local and systemic reactions, effects on asthma parameters

FAQ

  • What is Arrhenatherum Elatius and how is it being used in these clinical trials? Arrhenatherum Elatius is a type of grass pollen. In these trials, it's being used as part of a mixture in a skin prick test solution and potentially in an immunotherapy treatment for allergies caused by house dust mites.
  • Who can participate in these clinical trials? The trials are open to adults aged 18-65 with moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mites. Participants must meet specific criteria, including having symptoms for at least a year and showing positive reactions to certain allergy tests.
  • What is the main goal of these clinical trials? The main objective is to assess the effectiveness of the pollen mixture immunotherapy in reducing allergy symptoms, measured by the Total Combined Rhinitis Score (TCRS) after one year of treatment compared to a placebo.
  • How is the treatment administered in these trials? The treatment is given through subcutaneous immunotherapy, which means it's injected under the skin. Participants receive weekly injections during an initial up-dosing phase, followed by maintenance injections every 2-4 weeks.
  • What are some of the safety measures in place for these trials? The trials exclude people with severe immune disorders, active malignancies, and uncontrolled asthma. They also monitor for adverse events, local and systemic reactions, and effects on asthma parameters throughout the treatment period.

Ongoing Clinical Trials on Arrhenatherum Elatius

  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Bulgaria Germany Latvia Lithuania Poland

Glossary

  • Allergic Rhinitis: An allergic reaction affecting the nose, causing symptoms like sneezing, runny nose, and nasal congestion in response to allergens like pollen or dust mites.
  • Rhinoconjunctivitis: A condition where both the nose and eyes are affected by an allergic reaction, causing symptoms in both areas.
  • Subcutaneous Immunotherapy (SCIT): A treatment for allergies where small amounts of allergens are injected under the skin to help the body build tolerance over time.
  • House Dust Mite (HDM): Tiny insects that commonly live in house dust and can cause allergic reactions in some people.
  • Total Combined Rhinitis Score (TCRS): A measure used to assess the severity of allergy symptoms, combining scores for individual symptoms.
  • Placebo: A substance with no active medical effects, used as a control in clinical trials to compare against the actual treatment.
  • Nasal Provocation Test (NPT): A test where allergens are applied to the nose to measure the allergic response.
  • Immunoglobulin E (IgE): An antibody produced by the immune system in response to allergens, often elevated in allergic conditions.
  • Forced Expiratory Volume 1 (FEV1): A measure of lung function, indicating how much air a person can exhale in one second.
  • Rhinitis Medication Score (RMS): A score that measures the amount and type of medication needed to control allergy symptoms.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-purethal-mites-for-adults-with-moderate-to-severe-allergic-rhinitis-or-rhinoconjunctivitis-due-to-house-dust-mite-allergy/